Cancer death rates could be halved by 2030 with effective treatment

January 10, 2014
Cancer death rates could be halved by 2030 with effective treatment

(Medical Xpress)—UK cancer death rates are likely to fall more rapidly between now and 2013 than they have done in the previous 20 years, according to research presented today by the UCL School of Pharmacy.

Since 1990, age standardised cancer rates have fallen by over 20 per cent, but by 2030 they could drop by 50 per cent through more effective prevention, early stage diagnosis and better medicine and surgery. Authors of the report suggest that in areas such as bowel and treatment advances could be dramatic.

The research also highlighted how community pharmacy based services could increase cancer awareness and improve testing access and support.

The findings were presented at the UCL School of Pharmacy's annual New Year lecture at the Royal Society. Professor Jane Wardle (UCL Institute of Epidemiology and Health) presented the lecture on 'Harm Reduction and Health Improvement – the role of cancer awareness'.

Professor Wardle said: "Bowel cancer mortality in the UK could be halved in the coming one or two decades through lifestyle changes (including diets with less red and processed meat and more fibre and better weight control), the implementation of endoscopic screening for pre‐cancers and a higher uptake of stool‐based screening, combined with prompt help‐seeking for symptoms."

She added: "Greater willingness to take the actions required to support lifestyle change will be key to improving outcomes."

The need for increased professional and public awareness of the value of screening for precancerous conditions and detecting early stage cancer is emphasised in the research, which argues that community pharmacists could play an increasingly important 'public health' role by both improving medicines use and helping individuals and communities act on what is known about cancer prevention and early detection.

Seminar chair, Professor David Taylor (UCL School of Pharmacy), said: "In the past the NHS has not performed as well as some other services in facilitating the early detection and treatment of cancers. Fears about poor access to anticancer drugs (which in reality cost no more than 0.1 per cent of GDP) may also have undermined trust in the care provided by what is in overall terms still one of the best systems in the world."

He added: "But better approaches to public health improvement and more informed attitudes to talking about and assessing cancer risks and sharing information in ways that do not cause undue anxiety or excessive service demands are opening the way to better outcomes. There is little doubt that today's overall cancer will be well on the way to being halved by 2030."

Other contributors to the UCL School of Pharmacy seminar included Professor Anne Bowcock (Professor of Cancer Genomics at Imperial College), Dr Paul Catchpole of the ABPI and Professor Mark Emberton of University College London Hospital.

Professor Bowcock talked about the role of alterations in the BRCA1 and BRCA2 genes in breast cancer susceptibility and how research on cancer genetics will in future impact upon diagnosis and treatment.

Professor Emberton, who has pioneered the introduction of High Intensity Focused Ultrasound (HIFU) in prostate surgery, highlighted the facts all men should know about the value of PSA testing for prostate cancer. He described advances in diagnosing life threatening cancers and considered how future treatments will build on the 20 per cent decline in age standardised prostate rates seen in the UK since 1990.

Dr Paul Catchpole (ABPI's Director of Value and Access) addressed cancer drug funding and the extent to which the new Pharmaceutical Price Regulation Scheme now being introduced will enable all NHS patients who could benefit from treatment with new anti‐ medicines to access them.

Explore further: Prostate cancer deaths fall by a fifth in the last 20 years

Related Stories

Prostate cancer deaths fall by a fifth in the last 20 years

November 1, 2013
Death rates from prostate cancer have fallen by 20 per cent since the early 1990s according to new figures released by Cancer Research UK.

Cancer death rates drop by 20 per cent over 20 years

December 18, 2013
The death rate from cancer has dropped by more than a fifth since the 1990s according to the latest Cancer Research UK analysis released today (Wednesday).

Study highlights varying cancer survival rates across Europe

December 13, 2013
Cancer survival rates are continuing to improve in England, according to the results from a Europe-wide collaborative project.

Cancer Statistics 2014: Death rates continue to drop

January 7, 2014
The annual cancer statistics report from the American Cancer Society finds steady declines in cancer death rates for the past two decades add up to a 20 percent drop in the overall risk of dying from cancer over that time ...

Nomogram to determine individualized estimates of screen-detected prostate cancer overdiagnosis

January 6, 2014
Using a nomogram that incorporates age, Gleason score, and prostate-specific antigen (PSA) level at diagnosis, individual risks that a screen-detected prostate cancer has been overdiagnosed can be estimated, according to ...

Cancer trends tell tale of insufficient prevention

November 4, 2013
Australians are now developing cancer at slightly higher rates but dying of the disease less often, according to University of Sydney research published in the Medical Journal of Australia (MJA).

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.